We are applying mass spectrometry technology to study metabolic profiling studies in cancer development and progression . I have established a robust research program in bladder cancer research. Particularly, we have characterized metabolic alterations associated with smoking in bladder cancer, health disparity and more recently defined a role xenobiotic metabolism in bladder cancer progression. Importantly, these studies have resulted in multiple publications (European Urology Focus 2017, Cancer Prevention Research, 2017, Oncotarget 2017, Journal of Urology 2016). I have been collaborating extensively with clinicians to translate some of his findings to the area of biomarker development. Since joining Baylor College of Medicine as a core director, I have been instrumental in developing and establishing a state-of-the-art metabolomics core facility that has from an institutional wide entity to a Texas Medical Center wide service unit. Here I developed a unique unbiased mass spectrometry-based metabolic profiling platform in the area of cancer. I have also developed the methods for targeted profile, global metabolome and lipidome and most recently established the in vitro flux analysis platform, all of which are being heavily used to address key metabolic questions in area of cancer and metabolic diseases.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.